NCT02343042: Phase 1/2 - Selinexor and Backbone Treatments of Multiple Myeloma Patients (STOMP)

STOMP

Selinexor and Backbone Treatments of Multiple Myeloma Patients (STOMP)

This study will independently assess the efficacy and safety of 10 combination therapies in 11 arms, in dose-escalation/-evaluation and expansion phases, for the treatment of patients with relapsed/refractory multiple myeloma (RRMM) and newly diagnosed multiple myeloma (NDMM).

Selinexor and Backbone Treatments of Multiple Myeloma Patients (STOMP)

Sponsor

Karyopharm Therapeutics Inc

---

ClinicalTrials.gov Identifier: NCT02343042